




## Lixisenatide

Revised: December 3, 2018.

CASRN: 320367-13-3



## Drug Levels and Effects

### Summary of Use during Lactation

No information is available on the clinical use of lixisenatide during breastfeeding. Because lixisenatide is a large peptide molecule with a molecular weight of 4858 daltons, the amount in milk is likely to be very low and absorption is unlikely because it is probably destroyed in the infant's gastrointestinal tract. Until more data become available, lixisenatide should be used with caution during breastfeeding, especially while nursing a newborn or preterm infant.

### Drug Levels

*Maternal Levels.* Relevant published information was not found as of the revision date.

---

**Disclaimer:** Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

**Attribution Statement:** LactMed is a registered trademark of the U.S. Department of Health and Human Services.

*Infant Levels.* Relevant published information was not found as of the revision date.

### **Effects in Breastfed Infants**

Relevant published information was not found as of the revision date.

### **Effects on Lactation and Breastmilk**

Relevant published information was not found as of the revision date.

### **Alternate Drugs to Consider**

Acarbose, Glipizide, Glyburide, Insulin, Metformin, Miglitol

## **Substance Identification**

### **Substance Name**

Lixisenatide

### **CAS Registry Number**

320367-13-3

### **Drug Class**

Breast Feeding

Lactation

Hypoglycemic Agents

Incretins

Glucagon-Like Peptide-1 Agonists

GLP-1 Agonists